Correlating MD to NE tumor regions harboring EGFR amplification/CDKN2A deletion offers a means to assess regional cell proliferation, and identifying foci of cell proliferation enables a potential translational capability to implement targeted localized therapies. The gene discussed is EGFR; the disease is neoplasm.